Sunday, June 05, 2022 6:46:08 PM
2021-12-03
Insect cell baculovirus expression vector system (IC-BEVS) is one of the four major expression systems (insect cell, bacterial, yeast and mammalian cell expression systems).
With various advantages, IC-BEVS is an important source for the development of new drugs, materials and reagents, widely used for the study of recombinant protein expression[1], production of human and veterinary vaccines and for pharmaceutical application. For example, both Cervarix, GlaxoSmithKline's cervical cancer vaccine and Flubolk, Sanofi's tetravalent influenza vaccine adopt IC-BEVS.
The recombinant COVID-19 vaccine (Sf9 cell), jointly developed by WestVac Biopharma Co., Ltd. and the State/National Key Lab of Biotherapy, West China Hospital of Sichuan University, is also based on IC-BEVS, where the genes of SARS-CoV-2 are introduced into insect cells multiplied in the culture solution to prepare the SARS-CoV-2 S protein, inducing the human body to produce antibodies to block the viral infection. In addition, for the new generation vaccine against Delta and Omicron variants, WestVac has precisely designed the subunit vaccine antigen with stable self-assembled trimeric sequence, on the mature IC-BEVS platform. The vaccine has shown excellent immunogenicity and safety.
http://www.westvacpharma.com/detail/33
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM